Clinical trial · Observational
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
NCT06031779CI-TRIAL-00091703completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- gastric cancer
- label
- non-gastric cancer
Primary outcomes (1)
- measure
- serum bile acid profile before treatment
- timeFrame
- 1 month
Secondary outcomes (1)
- measure
- concentration of serum tumor markers before treatment
- timeFrame
- 1 month
- description
- CEA, CA19-9 and CA12-5
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age between 18-70, both gender; 2. The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy; 3. Informed consent was obtained. Exclusion Criteria: 1. The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc; 2. Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc; 3. Pregnant women; 4. Primary tumors of other systems were diagnosed; 5. Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis; 6. Patients with mental illness; 7. Patients who have received radiotherapy or surgery previously; 8. Those with poor adherence or difficult to follow up.
References
Publications (0)
Data not yet available
No reference posted for this study.